Apr 20, 2009 - SpePharm, a pan-European specialty pharmaceutical company dedicated to the provision of high medical value medicines in supportive and critical care, today announced the European introduction of two new products; MuGard® & Xerotin®, aimed at relieving some of the most debilitating side effects experienced by cancer patients. The European roll-out of MuGard® and Xerotin® starting this month with Germany, Italy, UK , Nordic countries and Greece. The rest of Europe will follow over the coming 12 to 18 months.
The details can be read here.
No comments:
Post a Comment